IDiyas

For the Inventor, By the Inventor

Tokyo, Japan

Toshifumi Asaka

USPTO Granted Patents = 22

 

Average Co-Inventor Count = 5.3

ph-index = 9

Forward Citations = 302(Granted Patents)


Location History:

  • Omiya, JP (1980)
  • Saitama, JP (1982 - 1994)
  • Ageo, JP (1987 - 1994)
  • Kounosu, JP (1995)
  • Tokyo, JP (1996 - 2001)
  • Konosu, JP (1998 - 2001)
  • Toshima-ku, JP (2012)

Company Filing History:

goldMedal22 out of 314 
 
Taisho Pharmaceutical Co., Ltd.
 patents

Years Active: 1980-2012

Loading Chart...
Loading Chart...
22 patents (USPTO):
1. 8124744 - Macrolide derivatives (2012-02-28),
2. 6191118 - Erythromycin A derivatives (2001-02-20),
3. 6169168 - Erythromycin A derivatives (2001-01-02),
4. 6165986 - Erythromycin a derivatives (2000-12-25),
5. 616598 - Erythromycin a derivatives (2000-12-26),
6. 6140479 - Erythromycin a derivatives (2000-10-31),
7. 5804565 - Erythromycin A derivatives (1998-09-08),
8. 5631355 - 5-O-desosaminylerythronolide a derivatives (1997-05-20),
9. 5631354 - 5-O-desosaminylerythronolide derivatives (1997-05-20),
10. 5602239 - 5-O-desosaminylerythronolide derivatives (1997-02-11),
11. 5591837 - 5-O-desosaminylerythronolide a derivative (1997-01-07),
12. 5523399 - 5-O-desosaminylerythronolide derivatives (1996-06-04),
13. 5403923 - 6-0-methylerythromycin A derivatives (1995-04-04),
14. 5350839 - 2'-position modified compound of erythromycin or its derivative (1994-09-27),
15. 5302705 - 6-O-methylerythromycin A oxime derivatives (1994-04-12),

Title: The Innovative Contributions of Toshifumi Asaka in Pharmaceutical Patents

Introduction: Toshifumi Asaka, based in Tokyo, Japan, stands out in the field of pharmaceutical innovations. With an impressive portfolio of 22 patents, Asaka's work has significantly advanced medical science, particularly in drug development targeting serious health conditions.

Latest Patents: Among his notable inventions are compounds related to macrolide derivatives. These compounds, represented by formula (I) and formula (IV), demonstrate strong inhibitory activity of MMP-9 production. This innovation presents a promising medicinal agent with fewer side effects compared to conventional MMP enzyme activity inhibitors. Asaka’s latest patent emphasizes its use as both a prophylactic and therapeutic drug for various conditions including oncogenic angiogenesis, chronic rheumatoid arthritis, and vascular diseases. Additionally, his patents include derivatives of Erythromycin A, showcasing his focused efforts on improving existing medicinal compounds.

Career Highlights: Toshifumi Asaka has dedicated his career to advancing pharmaceutical science. His extensive research and development efforts have led to innovative solutions for complex medical challenges. His patents reflect a commitment to enhancing therapeutic efficacy while minimizing adverse effects for patients.

Collaborations: Throughout his career, Asaka has collaborated with distinguished colleagues, including Masato Kashimura and Shigeo Morimoto. These collaborations have fostered an environment of creativity and innovation, allowing for the collective advancement of pharmaceutical technologies.

Conclusion: Toshifumi Asaka is a prominent figure in the field of pharmaceutical inventions with a notable impact through his 22 patents. His recent work with macrolide and Erythromycin A derivatives exemplifies his continuous dedication to improving medical treatments. As he continues his work with Taisho Pharmaceutical Co., Ltd., Asaka is set to maintain his influence in the pharmaceutical industry, contributing invaluable innovations to healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…